Today’s Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics
U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to 10 percent on $60 billion worth of U.S. in response to U.S. tariffs. The Dow Jones Industrial Average gained 0.71 percent to close at 26,246.96, while the S&P 500 Index hiked 0.54 percent to close at 2,904.31. The Nasdaq Composite Index jumped 0.76 percent to close at 7,956.11.
“In my opinion, I see President Trump as trying to force the trading partners to the bargaining table to renegotiate trade deals that have long favored other countries over the U.S. His methods are unconventional but the U.S. economy is strong, earnings are healthy and confidence among consumers and investors remains high,” said chief investment strategist at SlateStone Wealth, Robert Pavlik.
RDI Initiates Coverage on:
Madrigal Pharmaceuticals, Inc.
Cara Therapeutics, Inc.
Madrigal Pharmaceuticals’ stock moved 9.25% lower Tuesday, to close the day at $207.30. The stock recorded a trading volume of 986,655 shares, which was above its three months average volume of 190,743 shares. In the last year, Madrigal Pharmaceuticals’ shares have traded in a range of 20.16 – 325.98. The share price has gained 928.27% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $239.40 is above its 200-day moving average of $199.62. Shares of Madrigal Pharmaceuticals have fallen roughly 12.83 percent in the past month and are up 125.84 percent year-to-date.
Access RDI’s Madrigal Pharmaceuticals, Inc. Research Report at:
On Tuesday, shares of Cara Therapeutics recorded a trading volume of 1,177,167 shares, which was above the three months average volume of 955,696 shares. The stock ended the day 5.57% higher at $22.38. The share price has fallen 1.41% from its 52 week high with a 52 week trading range of 11.11 – 22.70. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $19.26 is above its 200-day moving average of $16.10. Shares of Cara Therapeutics have gained roughly 18.29 percent in the past month and are up 82.84 percent year-to-date.
Access RDI’s Cara Therapeutics, Inc. Research Report at:
Our Actionable Research on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Cara Therapeutics, Inc. (NYSE:CARA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.